Background While female sex has historically been associated with worse outcomes following surgical aortic valve replacement, ...

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinic ...

Cardamyst FDA approval and launch for PSVT, solid cash, and big expansion upside. Click for more on MIST stock.

Clinician-scientists at the University of Pittsburgh School of Medicine have developed an artificial intelligence (AI) tool ...

Scheimpflug-based pachymetry may inaccurately suggest corneal thinning after accelerated corneal crosslinking.

Natural appetite suppressants include fenugreek, glucomannan, coffee, green tea, and foods high in fiber, protein, and water.

On January 14, Liz Ann Sonders from Charles Schwab appeared on a CNBC Television interview to discuss the market volatility, ...

Microsoft alone runs approximately 100,000 A/B tests each year to continuously optimize products. A famous Gmail experiment, ...

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...